3-hydroxy-pyridin-4-ones useful for treating parasitic infections

• US 5,256,676 A
• Filed: 07/24/1992
• Issued: 10/26/1993
• Est. Priority Date: 04/27/1992
• Status: Expired due to Fees

• Current Assignee: British Technology Group Ltd. (Boston Scientific Corporation)
• Original Assignee: British Technology Group Ltd. (Boston Scientific Corporation)
• Inventors: Singh, Surinder, Whitehead, Susan, Peto, Timothy E. A., Hider, Robert C.
• Primary Examiner(s): Rotman, Alan L.
• Assistant Examiner(s): NORTHINGTON DAVIS, ZINNA
• Application Number:
  US07/918,080
• Time in Patent Office: 459 Days
• Field of Search: 546/296, 514/348
• US Class Current: 514/348
• CPC Class Codes: A61K 31/14 Quaternary ammonium compounds, e.g. edrophonium, choline betaines A61K31/205
• CPC Class Codes: A61K 31/44 Non condensed pyridines; Hydrogenated derivatives thereof
• CPC Class Codes: C07D 213/69 Two or more oxygen atoms
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

3-Hydroxypyridin-4-ones of formula (I) ##STR1## in which R₁ is a C₃ or C₄ hydroxyalkyl group in which the hydroxy group is terminally substituted on the alkyl group, R₂ is methyl or ethyl and R₃ and R₄ are each separately hydrogen, methyl or ethyl but with the proviso that the total number of carbon atoms in R₁ to R₄ is no more than six, the compound optionally being in the form of a physiologically acceptable salt and/or pro-drug thereof, are of value for the treatment of conditions caused by iron dependent parasites, particularly malaria.

Claims

1. A method for the treatment of a patient having a condition caused by an iron dependent parasite which comprises administering to that patient a therapeutically effective amount of a 3-hydroxypyridin-4-one of formula (I) ##STR6## in which R₁ is a C₃ or C₄ hydroxyalkyl group in which the hydroxy group is terminally substituted on the alkyl group, R₂ is methyl or ethyl and R₃ and R₄ are each separately hydrogen, methyl or ethyl but with the proviso that the total number of carbon atoms in R₁ to R₄ is no more than six, the compound optionally being in the form of a physiologically acceptable salt and/or pro-drug thereof.

2. A method according to claim 1, in which R₃ and R₄ are each hydrogen.

3. A method according to claim 1, in which R₂ is methyl.

4. A method according to claim 1, in which R₁ is a C₃ hydroxyalkyl group.

5. A method according to claim 1, in which R₁ is a straight chain hydroxyalkyl group.

6. A method according to claim 1, in which R₁ is 3-hydroxypropyl.

7. A method according to claim 1, in which the compound of formula (I) is 3-hydroxy-1-(3-hydroxypropyl)-2-methylpyridin-4-one.

8. A method according to claim 1, in which the compound of formula (I) is 3-hydroxy-1-(4-hydroxybutyl)-2-methylpyridin-4-one.

9. A method according to claim 1, in which the compound of formula (I) is 2-ethyl-3-hydroxy-1-(3-hydroxypropyl)pyridin-4-one or 2-ethyl-3-hydroxy-1-(4-hydroxybutyl)pyridin-4-one.

10. A method according to claim 1, in which the patient has malaria.